In the ANECOVA approach, the zygotes are placed in the maternal uterine cavity over all early development stages to get the benefits of a customized and adapted environment. The injected ovocytes are directly placed in the ANECOVA device which is then placed within the uterine cavity for the desired period. Formed embryos are then recovered and after the usual selection process, the required number is transferred as in the traditional embryo transfer procedure.

The first ANECOVA device thus restores the fertilization and early embryonic development phases back into the physiological environment of the maternal uterus instead of the laboratory incubator. This permits the development of the embryos in close communication and exchange with maternal factors from the very start of life.

A positive influence is expected on both the number and the individual quality of the embryos thus produced which should translate into better overall results of assisted reproduction.

The preliminary results already obtained have been extremely encouraging. ANECOVA is currently in the process of conducting clinical evaluation programs in close collaboration with international experts in the field, pursuing its quest for the highest quality of medical solutions to bring to patients worldwide.